Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$46.43
At close: May 27, 4:00 PM EDT
$46.43
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Protagonist Therapeutics Analyst Ratings and Price Targets | NASDAQ:PTGX | Benzinga
Protagonist Therapeutics Inc has a consensus price target of $60.27 based on the ratings of 12 analysts. The high is $80 issued by HC Wainwright & Co. on May 19, 2025. The low is $35 issued by Piper Sandler on July 3, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Wedbush on May 19, 2025, April 10, 2025, and March 28, 2025, respectively. With an average price target of $76.67 between HC Wainwright & Co., HC Wainwright & Co., and Wedbush, there's an implied 65.12% upside for Protagonist Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Truist Securities
BMO Capital
Citizens Capital Markets
1calculated from analyst ratings
Analyst Ratings for Protagonist Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/19/2025 | Buy Now | 72.3% | HC Wainwright & Co. | Douglas Tsao51% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2025 | Buy Now | 72.3% | HC Wainwright & Co. | Douglas Tsao51% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2025 | Buy Now | 50.76% | Wedbush | Yun Zhong34% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2025 | Buy Now | 63.69% | Truist Securities | Srikripa Devarakonda44% | $60 → $76 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 55.07% | BMO Capital | Etzer Darout44% | $62 → $72 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2025 | Buy Now | 72.3% | HC Wainwright & Co. | Douglas Tsao51% | $54 → $80 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 31.38% | Citizens Capital Markets | Jonathan Wolleben69% | $61 → $61 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/10/2025 | Buy Now | 16.3% | HC Wainwright & Co. | Douglas Tsao51% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 22.77% | JP Morgan | Brian Cheng38% | $53 → $57 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | 16.3% | HC Wainwright & Co. | Douglas Tsao51% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | -18.16% | Goldman Sachs | — | $43 → $38 | Maintains | Neutral | Get Alert |
| 02/24/2025 | Buy Now | 16.3% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $54 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 24.92% | JMP Securities | Jonathan Wolleben69% | $58 → $58 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/07/2025 | Buy Now | 7.69% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 14.15% | JP Morgan | Brian Cheng38% | $51 → $53 | Maintains | Overweight | Get Alert |
| 12/10/2024 | Buy Now | 7.69% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | 33.53% | BMO Capital | Etzer Darout44% | → $62 | Initiates | → Outperform | Get Alert |
| 11/22/2024 | Buy Now | 7.69% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 7.69% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 7.69% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 24.92% | Wedbush | Yun Zhong34% | → $58 | Initiates | → Outperform | Get Alert |
| 09/24/2024 | Buy Now | 40% | TD Cowen | Tara Bancroft57% | → $65 | Initiates | → Buy | Get Alert |
| 09/12/2024 | Buy Now | 7.69% | HC Wainwright & Co. | Douglas Tsao51% | $40 → $50 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 29.23% | Truist Securities | Srikripa Devarakonda44% | → $60 | Initiates | → Buy | Get Alert |
| 08/07/2024 | Buy Now | -7.39% | JMP Securities | Jonathan Wolleben69% | $45 → $43 | Maintains | Market Outperform | Get Alert |
| 08/07/2024 | Buy Now | -13.85% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $40 | Maintains | Buy | Get Alert |
| 07/25/2024 | Buy Now | 3.38% | JP Morgan | Brian Cheng38% | $39 → $48 | Maintains | Overweight | Get Alert |
| 07/24/2024 | Buy Now | 9.84% | BTIG | Julian Harrison37% | $41 → $51 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | -3.08% | JMP Securities | Jonathan Wolleben69% | $45 → $45 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/14/2024 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | -3.08% | JMP Securities | Jonathan Wolleben69% | $42 → $45 | Maintains | Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | -9.54% | JMP Securities | Jonathan Wolleben69% | $42 → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | -20.31% | JP Morgan | Brian Cheng38% | $34 → $37 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -20.31% | JMP Securities | Jonathan Wolleben69% | $35 → $37 | Maintains | Market Outperform | Get Alert |
| 10/30/2023 | Buy Now | — | Capital One | Tim Chiang37% | — | Initiates | → Overweight | Get Alert |
| 10/10/2023 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | Buy Now | -26.77% | JP Morgan | Brian Cheng38% | $36 → $34 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | -24.62% | JMP Securities | Jonathan Wolleben69% | $28 → $35 | Maintains | Market Outperform | Get Alert |
| 07/03/2023 | Buy Now | -24.62% | Piper Sandler | Yasmeen Rahimi55% | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 07/03/2023 | Buy Now | -11.7% | BTIG | Julian Harrison37% | → $41 | Reiterates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/27/2023 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | -39.69% | JMP Securities | Jonathan Wolleben69% | $31 → $28 | Maintains | Market Outperform | Get Alert |
| 03/16/2023 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao51% | $33 → $38 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | -33.23% | JMP Securities | Jonathan Wolleben69% | $21 → $31 | Maintains | Market Outperform | Get Alert |
| 11/10/2022 | Buy Now | -28.93% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $33 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | -54.77% | JMP Securities | Jonathan Wolleben69% | → $21 | Reinstates | → Market Outperform | Get Alert |
FAQ
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by HC Wainwright & Co. on May 19, 2025. The analyst firm set a price target for $80.00 expecting PTGX to rise to within 12 months (a possible 72.30% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protagonist Therapeutics (PTGX)?
The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by HC Wainwright & Co., and Protagonist Therapeutics reiterated their buy rating.
When was the last upgrade for Protagonist Therapeutics (PTGX)?
There is no last upgrade for Protagonist Therapeutics
When was the last downgrade for Protagonist Therapeutics (PTGX)?
There is no last downgrade for Protagonist Therapeutics.
When is the next analyst rating going to be posted or updated for Protagonist Therapeutics (PTGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
Is the Analyst Rating Protagonist Therapeutics (PTGX) correct?
While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a reiterated with a price target of $80.00 to $80.00. The current price Protagonist Therapeutics (PTGX) is trading at is $46.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
